Your session is about to expire
← Back to Search
Intervention Management Arm (Dapagliflozin) for Atrial Fibrillation (DAPA-AF Trial)
DAPA-AF Trial Summary
This trial is testing whether the diabetes medication dapagliflozin can help prevent AF following surgery to treat AF. 100 people with AF will be enrolled and randomly assigned to receive either dapagliflozin or placebo. The trial will follow participants for 12 months to see how often AF occurs.
DAPA-AF Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DAPA-AF Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What health conditions has Intervention Management Arm (Dapagliflozin) been used to address?
"Intervention Management Arm (Dapagliflozin) is a popular pharmaceutical treatment for many medical conditions, including diet and exercise management as well as inadequate response to monotherapy."
In what geographic regions is this exploration accessible?
"The current list of medical centres participating in this study include Maine Medical Center, Henry Ford Hospital, St. Luke's Hospital and Health Network, as well as 5 other facilities."
Is this research opportunity currently recruiting participants?
"According to the information available on clinicaltrials.gov, this particular trial has concluded recruitment since its last update on October 7th 2022. It was initially posted on July 27 2021 and is no longer accepting applicants at present; however, there are 539 other studies that are actively seeking participants right now."
Could you detail the other investigations that have been conducted surrounding Intervention Management Arm (Dapagliflozin)?
"Intervention Management Arm (Dapagliflozin) was originally researched at the University of Texas Health Science Centre in San Antonio back in 2014. As it stands, 18456 studies have been concluded while 63 are still open and recruiting participants, with numerous trials taking place in Portland Maine."
What is the aggregate figure of individuals involved in this experiment?
"This trial is no longer recruiting patients, having been initially posted on July 27th 2021 and last updated October 7th 2022. However, if you are looking for other studies related to atrial fibrillation there are currently 476 trials actively enrolling participants or 63 clinical trials involving Intervention Management Arm (Dapagliflozin)."
Is this the initial exploration of its kind?
"Since 2014, Intervention Management Arm (Dapagliflozin) has been a popular subject of medical research. AstraZeneca first commissioned the initial trial in that year with 700 participants and later received N/A drug approval following its publication. Nowadays there are 63 ongoing experiments for this medication across 235 cities and 50 countries."
How does Dapagliflozin affect human health and wellbeing?
"Our experts at Power rated Intervention Management Arm (Dapagliflozin)'s safety as a 3 due to its Phase 4 trial status, signifying that this treatment is already authorized."
Share this study with friends
Copy Link
Messenger